Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2023

Open Access 28-07-2023 | Cetuximab | short review

Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma

Authors: Florian Kocher, MD, PhD, Andreas Seeber, MD, PhD

Published in: memo - Magazine of European Medical Oncology | Issue 3/2023

Login to get access

Summary

This short review gives an overview of current treatment concepts, recently published trials, and novel developments in relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) not amendable for local curative treatment. Trials with potential future clinical implications and relevant updates of landmark trials are provided as well.
Literature
1.
Machiels JP, Leemans RC, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462–75.CrossRefPubMed
2.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–28.CrossRefPubMed
3.
Tahara MGR, Rischin D, Harrington KJ, Burtness B, De Castro G Jr., Psyrri A, Brana I, Neupane P, Bratland A, Fuereder T, Hughes BGM, Mesia Nin R, Ngamphaiboon N, Rordorf T, Ishak WWZ, Lin J, Gumuscu B, Lerman N, Soulieres D. Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5‑year results from KEYNOTE-048. Ann Oncol. 2022;33:S295–S322.CrossRef
4.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, et al. Nivolumab plus Ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of checkmate 651. J Clin Oncol. 2023;41(12):2166–80.CrossRefPubMed
5.
Psyrri A, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol. 2023;34(3):262–74.CrossRefPubMed
6.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.CrossRefPubMed
7.
Papanastasopoulos P, Stebbing J. Molecular basis of 5‑fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 2014;34(4):1531–5.PubMed
8.
Saif MW. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5‑FU- and capecitabine-related toxicity using full sequencing of DPYD. Cancer Genomics Proteomics. 2013;10(2):89–92.PubMed
9.
10.
Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562–7.CrossRefPubMed
11.
Dzienis MRCJ, Fuentes CS, Hansen AR, Nordlinger MJ, Pastor AV, Oppelt P, Neki A, Gregg AW, Lima IPF, Franke FA, da Cunha JGF, Tseng JE, Loree T, Joshi AJ, Mccarthy JS, Naicker N, Sidi Y, Gumuscu B, De Castro G. Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study. Ann Oncol. 2022;33:S839–S40.CrossRef
12.
Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, et al. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat Med. 2023;29(4):880–7.CrossRefPubMedPubMedCentral
13.
Taylor MH, Lee CH, Makker V, Rasco D, Dutcus CE, Wu J, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 2020;38(11):1154–63.CrossRefPubMedPubMedCentral
14.
Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22(6):883–92.CrossRefPubMed
15.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463–75.CrossRefPubMed
16.
Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr., et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand‑1 combined positive score. J Clin Oncol. 2022;40(21):2321–32.CrossRefPubMedPubMedCentral
Metadata
Title
Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma
Authors
Florian Kocher, MD, PhD
Andreas Seeber, MD, PhD
Publication date
28-07-2023
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00901-5

Other articles of this Issue 3/2023

memo - Magazine of European Medical Oncology 3/2023 Go to the issue

short review

ASH highlights 2022—multiple myeloma

leading article

Emerging molecular drugs for the treatment of gastroesophageal tumors

short review

Lipid nanoparticles in the treatment of lung cancer—hype or hope?

editorial

Head and neck cancer revisited

editorial

Long-term survival and follow-up care after cancer in Austria

short review

Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits